Urogen Pharma

Urogen Pharma EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Urogen Pharma (URGN) as of Nov 12, 2026 is -125.53 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -96.78 M USD — a change of 29.71% (lower).

EBITDA

-125.53 MUSD

YoY

29.71%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Urogen Pharma is 2025 -125.53 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Urogen Pharma was 2024 -96.78 M USD. It decreases by 29.71% lower compared to the previous year.

The Urogen Pharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-77.18 M USD
Jan 1, 2019
-109.48 M USD
Jan 1, 2020
-126.74 M USD
Jan 1, 2021
-92.29 M USD
Jan 1, 2022
-79.04 M USD
Jan 1, 2023
-62.06 M USD
Jan 1, 2024
-96.78 M USD
Jan 1, 2025
-125.53 M USD
The Urogen Pharma EBITDA history
YEAREBITDAYoY
-125.53 MUSD+29.71%
-96.78 MUSD+55.96%
-62.06 MUSD-21.49%
-79.04 MUSD-14.36%
-92.29 MUSD-27.18%
-126.74 MUSD+15.77%
-109.48 MUSD+41.85%
-77.18 MUSD+286.87%
-19.95 MUSD-2,600.00%
798,000.00USD-106.43%
-12.41 MUSD+184.05%
-4.37 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Urogen Pharma Stock analysis

What does Urogen Pharma do? Urogen Pharma Ltd is a biopharmaceutical company specializing in the development and marketing of innovative therapies for urological diseases. The company was founded in Israel in 2004 and is headquartered in Ra'anana. Answer: Urogen Pharma Ltd is a biopharmaceutical company specializing in the development and marketing of innovative therapies for urological diseases. Urogen Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Urogen Pharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Urogen Pharma is -125.53 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Urogen Pharma changed from -96.78 M USD to -125.53 M USD, representing a 29.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Urogen Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Urogen Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Urogen Pharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Urogen Pharma